A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund ’s adjuvant in melanoma patients

ConclusionsLPS and polyICLC are safe and effective vaccine adjuvants when combined with IFA. Contrary to the central hypothesis, IFA enhanced T cell responses to peptide vaccines when added to TLR agonists. Future studies will aim to understand mechanisms underlying the favorable effects with IFA.Trial registrationThe clinical trial Mel58 was performed with IRB (#15781) and FDA approval and is registered withClinicaltrials.gov on April 25, 2012 (NCT01585350). Patients provided written informed consent to participate. Enrollment started on June 24, 2012.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research